These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
81 related articles for article (PubMed ID: 28796141)
1. Therapeutic Potential for FGFR Inhibitors in SOX9-FGFR2 Coexpressing Pancreatic Cancer. OʼSullivan H; Kelleher FC; Lavelle M; McGovern B; Murphy J; Swan N; McDermott R Pancreas; 2017 Sep; 46(8):e67-e69. PubMed ID: 28796141 [No Abstract] [Full Text] [Related]
2. FGF10/FGFR2 signal induces cell migration and invasion in pancreatic cancer. Nomura S; Yoshitomi H; Takano S; Shida T; Kobayashi S; Ohtsuka M; Kimura F; Shimizu H; Yoshidome H; Kato A; Miyazaki M Br J Cancer; 2008 Jul; 99(2):305-13. PubMed ID: 18594526 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of SOX9 expression in pancreatic ductal adenocarcinoma and intraductal papillary mucinous neoplasm. Tanaka T; Kuroki T; Adachi T; Ono S; Hirabaru M; Soyama A; Kitasato A; Takatsuki M; Hayashi T; Eguchi S Pancreas; 2013 Apr; 42(3):488-93. PubMed ID: 23146920 [TBL] [Abstract][Full Text] [Related]
4. Celecoxib suppresses fibroblast growth factor-2 expression in pancreatic ductal adenocarcinoma PANC-1 cells. Li J; Luo M; Wang Y; Shang B; Dong L Oncol Rep; 2016 Sep; 36(3):1345-52. PubMed ID: 27430377 [TBL] [Abstract][Full Text] [Related]
5. FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro. Künstlinger H; Fassunke J; Schildhaus HU; Brors B; Heydt C; Ihle MA; Mechtersheimer G; Wardelmann E; Büttner R; Merkelbach-Bruse S Oncotarget; 2015 Aug; 6(24):20215-30. PubMed ID: 26036639 [TBL] [Abstract][Full Text] [Related]
6. Clinical implication of Sox9 and activated Akt expression in pancreatic ductal adenocarcinoma. Xia S; Feng Z; Qi X; Yin Y; Jin J; Wu Y; Wu H; Feng Y; Tao M Med Oncol; 2015 Jan; 32(1):358. PubMed ID: 25428381 [TBL] [Abstract][Full Text] [Related]
7. NFATc1 Links EGFR Signaling to Induction of Sox9 Transcription and Acinar-Ductal Transdifferentiation in the Pancreas. Chen NM; Singh G; Koenig A; Liou GY; Storz P; Zhang JS; Regul L; Nagarajan S; Kühnemuth B; Johnsen SA; Hebrok M; Siveke J; Billadeau DD; Ellenrieder V; Hessmann E Gastroenterology; 2015 May; 148(5):1024-1034.e9. PubMed ID: 25623042 [TBL] [Abstract][Full Text] [Related]
8. Deciphering role of FGFR signalling pathway in pancreatic cancer. Kang X; Lin Z; Xu M; Pan J; Wang ZW Cell Prolif; 2019 May; 52(3):e12605. PubMed ID: 30945363 [TBL] [Abstract][Full Text] [Related]
9. FAK and paxillin, two potential targets in pancreatic cancer. Kanteti R; Batra SK; Lennon FE; Salgia R Oncotarget; 2016 May; 7(21):31586-601. PubMed ID: 26980710 [TBL] [Abstract][Full Text] [Related]
10. Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. St Bernard R; Zheng L; Liu W; Winer D; Asa SL; Ezzat S Endocrinology; 2005 Mar; 146(3):1145-53. PubMed ID: 15564323 [TBL] [Abstract][Full Text] [Related]
12. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Brooks AN; Kilgour E; Smith PD Clin Cancer Res; 2012 Apr; 18(7):1855-62. PubMed ID: 22388515 [TBL] [Abstract][Full Text] [Related]
13. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459 [TBL] [Abstract][Full Text] [Related]
14. A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma. Wang L; Šuštić T; Leite de Oliveira R; Lieftink C; Halonen P; van de Ven M; Beijersbergen RL; van den Heuvel MM; Bernards R; van der Heijden MS Eur Urol; 2017 Jun; 71(6):858-862. PubMed ID: 28108151 [TBL] [Abstract][Full Text] [Related]
15. Use of a preclinical model of pancreas cancer to identify potential candidates for rapalogue therapy. Takeuchi KK; Crawford HC Gut; 2014 Sep; 63(9):1379-80. PubMed ID: 24966285 [No Abstract] [Full Text] [Related]
16. SOX9 inhibits β-TrCP-mediated protein degradation to promote nuclear GLI1 expression and cancer stem cell properties. Deng W; Vanderbilt DB; Lin CC; Martin KH; Brundage KM; Ruppert JM J Cell Sci; 2015 Mar; 128(6):1123-38. PubMed ID: 25632159 [TBL] [Abstract][Full Text] [Related]
17. Overexpression of fibroblast growth factor receptor 4 in high-grade pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. Motoda N; Matsuda Y; Onda M; Ishiwata T; Uchida E; Naito Z Int J Oncol; 2011 Jan; 38(1):133-43. PubMed ID: 21109934 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties. Bono F; De Smet F; Herbert C; De Bock K; Georgiadou M; Fons P; Tjwa M; Alcouffe C; Ny A; Bianciotto M; Jonckx B; Murakami M; Lanahan AA; Michielsen C; Sibrac D; Dol-Gleizes F; Mazzone M; Zacchigna S; Herault JP; Fischer C; Rigon P; Ruiz de Almodovar C; Claes F; Blanc I; Poesen K; Zhang J; Segura I; Gueguen G; Bordes MF; Lambrechts D; Broussy R; van de Wouwer M; Michaux C; Shimada T; Jean I; Blacher S; Noel A; Motte P; Rom E; Rakic JM; Katsuma S; Schaeffer P; Yayon A; Van Schepdael A; Schwalbe H; Gervasio FL; Carmeliet G; Rozensky J; Dewerchin M; Simons M; Christopoulos A; Herbert JM; Carmeliet P Cancer Cell; 2013 Apr; 23(4):477-88. PubMed ID: 23597562 [TBL] [Abstract][Full Text] [Related]
19. Targeting fibroblast growth factor receptor pathway in breast cancer. Criscitiello C; Esposito A; De Placido S; Curigliano G Curr Opin Oncol; 2015 Nov; 27(6):452-6. PubMed ID: 26397764 [TBL] [Abstract][Full Text] [Related]
20. Overview of pre-clinical and clinical studies targeting angiogenesis in pancreatic ductal adenocarcinoma. Craven KE; Gore J; Korc M Cancer Lett; 2016 Oct; 381(1):201-10. PubMed ID: 26723874 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]